Adipotide (FTTP): Vascular-Targeted Fat Reduction Research & Prohibitin Studies

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is Adipotide (FTTP)?

Adipotide, also known as FTTP (Fat-Targeted Proapoptotic Peptide) or Prohibitin-TP01, is a synthetic chimeric peptide designed to selectively target and destroy blood vessels supplying white adipose tissue. Developed at the University of Texas MD Anderson Cancer Center by the research teams of Wadih Arap and Renata Pasqualini, Adipotide represents a fundamentally different approach to fat reduction research compared to metabolic or hormonal strategies such as GLP-1 receptor agonists or growth hormone secretagogues.

The peptide is “chimeric” in the sense that it is composed of two functionally distinct peptide sequences joined together, each performing a separate role. The first sequence acts as a homing device, directing the peptide to blood vessels that feed fat tissue. The second sequence acts as a cell-killing payload, triggering programmed cell death in the targeted vascular cells. This dual-function design draws directly from vascular targeting strategies originally developed in cancer research, where the selective destruction of tumor blood supply has been a longstanding area of investigation.

Adipotide gained significant attention following a 2011 study published in Science Translational Medicine that demonstrated substantial fat reduction in obese rhesus monkeys. That study, discussed in detail below, remains the most prominent piece of published research on the compound and the primary basis for scientific interest in its mechanism.

It is important to note from the outset that Adipotide has not been tested in human clinical trials, has not been approved by any regulatory agency for therapeutic use, and carries significant safety concerns identified in primate studies — particularly regarding renal toxicity. This guide presents the published research as objectively as possible, including both the promising findings and the substantial limitations.

Mechanism of Action

Adipotide’s mechanism of action is distinct from virtually all other compounds studied in the context of fat reduction. Rather than modulating appetite, altering metabolic rate, or influencing lipid metabolism, Adipotide works by selectively destroying the blood vessels that supply white adipose tissue. This vascular targeting approach causes the fat tissue itself to undergo ischemia (loss of blood supply) and subsequent apoptosis (programmed cell death), effectively “starving” fat deposits of their vascular support.

The Targeting Sequence: CKGGRAKDC

The first component of Adipotide is a nine-amino-acid peptide with the sequence CKGGRAKDC. This targeting domain was identified through phage display screening — a technique in which large libraries of random peptide sequences are tested for their ability to bind specific biological targets. The CKGGRAKDC sequence was found to bind with high affinity to prohibitin, a protein expressed on the surface of endothelial cells lining the blood vessels of white adipose tissue.

Prohibitin is a multifunctional protein that, in addition to its intracellular roles in mitochondrial function and cell signaling, is displayed on the luminal surface of the adipose vasculature. This surface expression pattern is what makes prohibitin a viable target for vascular homing strategies. Importantly, while prohibitin is expressed in various tissues throughout the body, its surface expression on the endothelium appears to be enriched in the vasculature supplying white fat depots, providing a degree of tissue selectivity.

The Proapoptotic Payload: D(KLAKLAK)₂

The second component of Adipotide is the synthetic peptide sequence D(KLAKLAK)₂, a well-characterized proapoptotic motif. This sequence is composed of D-amino acids (the mirror-image forms of standard L-amino acids), which confer resistance to proteolytic degradation — an important feature for maintaining biological activity in vivo. The D(KLAKLAK)₂ sequence was originally designed as a mitochondria-disrupting peptide. Upon internalization into target cells, it localizes to mitochondrial membranes, where it disrupts membrane integrity and triggers the intrinsic apoptotic cascade. This leads to cytochrome c release, caspase activation, and ultimately programmed cell death.

The use of D(KLAKLAK)₂ as a cell-killing payload is not unique to Adipotide. This sequence has been employed in multiple vascular targeting constructs in cancer research, where it has been conjugated to various tumor-homing peptides to destroy tumor vasculature. Adipotide essentially repurposes this anti-cancer strategy for adipose tissue targeting.

The Combined Mechanism

When the two sequences are joined into the chimeric Adipotide peptide, the mechanism proceeds in a series of steps: (1) the CKGGRAKDC homing domain directs the peptide to prohibitin-expressing endothelial cells in the adipose vasculature; (2) the peptide is internalized by the target cells via receptor-mediated endocytosis; (3) the D(KLAKLAK)₂ payload disrupts mitochondrial membranes within the endothelial cells; (4) the endothelial cells undergo apoptosis, destroying the blood vessel wall; (5) loss of vascular supply causes the surrounding adipose tissue to undergo ischemic death and resorption.

This mechanism is fundamentally different from GLP-1 receptor agonists (which modulate appetite and glucose metabolism), from lipolytic peptides such as AOD-9604 (which influence lipid mobilization from adipocytes), and from thermogenic approaches (which increase energy expenditure). Adipotide does not address the adipocytes directly — it eliminates their blood supply, which secondarily causes tissue death.

Research Applications

The Rhesus Monkey Obesity Study (2011)

The most significant published study on Adipotide was conducted by Barnhart et al. and published in Science Translational Medicine in 2011. This study investigated the effects of Adipotide administration in obese, spontaneously hyperinsulinemic rhesus monkeys — a primate model chosen for its physiological similarity to human obesity.

Over a 28-day treatment period, Adipotide-treated monkeys demonstrated an average body weight reduction of approximately 11% and a 39% reduction in abdominal adiposity as measured by MRI. These changes were accompanied by improvements in insulin resistance parameters, including reductions in body mass index and waist circumference. The magnitude of fat loss observed in this study was striking and generated considerable interest in the scientific and popular press at the time of publication.

The study provided direct evidence for Adipotide’s proposed mechanism: histological analysis of adipose tissue from treated animals showed vascular destruction and adipocyte apoptosis consistent with the ischemic mechanism described above. Treated fat depots exhibited reduced vascularity, increased markers of apoptosis, and tissue remodeling indicative of fat resorption.

However, the study also identified significant safety signals, discussed in the Safety Profile section below, which have tempered enthusiasm for Adipotide’s translational potential.

Vascular Biology and Prohibitin Research

Beyond its direct application to fat reduction, Adipotide has served as an important research tool in the study of vascular biology and prohibitin function. The identification of prohibitin as a surface marker on adipose vasculature opened new avenues of investigation into how different vascular beds maintain distinct molecular identities, and how these identities can be exploited for tissue-specific drug delivery.

Research using the CKGGRAKDC homing peptide (independent of the proapoptotic payload) has contributed to understanding the “vascular zip codes” concept — the principle that blood vessels in different organs and tissues express distinct surface receptors that can be targeted by circulating ligands. This concept, pioneered in large part by the Arap and Pasqualini laboratories, has implications far beyond adipose tissue, extending to targeted drug delivery in oncology, cardiology, and other fields.

Cancer Vasculature Targeting

Adipotide’s design lineage traces directly to anti-cancer vascular targeting research. The strategy of conjugating a tissue-homing peptide to a proapoptotic payload was first developed to destroy tumor blood supply, and Adipotide represents the application of this strategy to a non-cancerous tissue context. Research in this area continues to explore various homing peptide-payload combinations for selective destruction of pathological vasculature, with Adipotide serving as a proof-of-concept for the broader approach.

Obesity Research and Comparative Approaches

In the broader landscape of obesity research, Adipotide occupies a unique mechanistic niche. While most pharmacological approaches to obesity target appetite regulation (GLP-1 agonists, MC4R agonists), metabolic rate (thyroid hormone analogs, uncoupling agents), or lipid handling (lipase inhibitors, lipolytic peptides), Adipotide targets the vascular infrastructure supporting fat tissue. This distinction has made it a subject of interest in comparative studies examining different approaches to adipose tissue reduction.

Researchers investigating fat biology have used Adipotide as a tool to study the consequences of acute adipose vascular disruption, including the metabolic effects of rapid fat loss, the inflammatory response to adipose tissue necrosis, and the body’s compensatory mechanisms following loss of fat depots. For researchers specifically interested in lipolytic peptide mechanisms, the AOD-9604 research guide provides context on an alternative approach to fat metabolism research.

Dosing in Published Research

The following table summarizes dosing protocols used in published Adipotide research. These doses were used in animal models and have not been validated for human use. No human dosing protocol exists for Adipotide.

Parameter	Published Protocol (Primate Study)	Notes
Species	Rhesus monkey (Macaca mulatta)	Obese, spontaneously hyperinsulinemic
Dose	0.43 mg/kg/day	Subcutaneous injection
Treatment duration	28 days	Daily administration
Route	Subcutaneous injection	Administered in abdominal region
Vehicle	Sterile saline	—
Observed weight loss	~11% body weight	Over 28-day period
Observed fat reduction	~39% abdominal fat (MRI)	Over 28-day period

Important: Allometric scaling from primate to human doses is not straightforward. Body surface area scaling, differences in renal clearance, and species-specific pharmacokinetics all influence dose translation. Direct extrapolation of the primate dose to a hypothetical human equivalent is not scientifically valid without formal pharmacokinetic studies. No human pharmacokinetic data exists for Adipotide.

Reconstitution and Handling

Research-grade Adipotide is typically supplied as a lyophilized (freeze-dried) powder. Proper reconstitution and handling are essential for maintaining peptide integrity in experimental settings.

Parameter	Recommendation
Reconstitution solvent	Bacteriostatic water (0.9% benzyl alcohol)
Reconstitution technique	Direct solvent gently down the vial wall; do not shake vigorously. Allow the lyophilized pellet to dissolve gradually. Gentle swirling is acceptable if needed.
Storage (lyophilized)	-20°C or below, protected from light and moisture
Storage (reconstituted)	2–8°C (refrigerated); use within 21–28 days
Avoid	Repeated freeze-thaw cycles, prolonged room temperature exposure, direct sunlight
Handling	Use sterile technique; alcohol-swab vial stopper before each withdrawal

As a chimeric peptide containing D-amino acid residues, Adipotide has enhanced resistance to proteolytic degradation compared to standard L-amino acid peptides. However, the disulfide bond implied by the two cysteine residues in the CKGGRAKDC targeting domain may be susceptible to reduction under improper storage conditions. Maintaining an appropriate storage environment and avoiding exposure to reducing agents is important for preserving structural integrity.

Safety Profile

The safety profile of Adipotide represents the most significant barrier to its translational development. While the 2011 primate study demonstrated impressive fat reduction, it also revealed concerning adverse effects that must be thoroughly understood by any researcher working with this compound.

Renal Toxicity

The most prominent safety signal from the rhesus monkey study was renal toxicity. Treated animals exhibited signs of kidney stress, including elevated serum creatinine and evidence of tubular damage on histological examination. The kidney, as a highly vascularized organ with dense capillary networks, appears to be vulnerable to off-target effects from Adipotide’s vascular disruption mechanism. While prohibitin surface expression is enriched in adipose vasculature, it is not exclusively expressed there — renal vasculature also displays prohibitin, making the kidney a predictable site of off-target toxicity.

The authors of the 2011 study noted that renal effects were dose-dependent and partially reversible upon cessation of treatment, but the severity of the findings was sufficient to raise significant concerns about the therapeutic window of the compound. Any dose high enough to produce meaningful fat reduction also appeared to carry risk of renal impairment.

Tissue Selectivity Limitations

The renal toxicity finding highlights a fundamental challenge of Adipotide’s mechanism: prohibitin is not uniquely expressed on adipose vasculature. While the CKGGRAKDC homing peptide shows preferential binding to adipose blood vessels, the selectivity is not absolute. Other highly vascularized tissues — kidneys, liver, lungs — may also be affected to varying degrees. This incomplete tissue selectivity is a common challenge in vascular targeting strategies, whether applied to cancer or to other conditions.

Inflammatory Response

The destruction of adipose vasculature and subsequent fat tissue necrosis generates an inflammatory response as the body resorbs dead tissue. In the primate study, treated animals showed evidence of local and systemic inflammatory markers. While some degree of inflammation is expected with any tissue remodeling process, the scale of tissue destruction caused by Adipotide raises questions about potential complications from excessive or prolonged inflammatory responses, particularly in the context of repeated or prolonged dosing.

No Human Safety Data

Adipotide has not undergone any human clinical trials, including Phase I safety studies. As a result, there is no formal characterization of Adipotide’s safety profile in humans. The human pharmacokinetic properties (absorption, distribution, metabolism, excretion), potential drug interactions, long-term effects, and adverse event profile are entirely unknown. All safety information is derived from primate and rodent models, and interspecies differences in vascular biology, renal function, and immune response make direct extrapolation uncertain.

Immunogenicity Considerations

As a synthetic peptide, Adipotide has the potential to elicit immune responses upon repeated administration. The chimeric structure, which includes both L-amino acid and D-amino acid components, may present epitopes recognized by the immune system. Antibody formation against Adipotide could theoretically reduce efficacy over time or, in more severe cases, cause hypersensitivity reactions. The 28-day primate study was not designed to fully characterize immunogenicity, and longer-term studies would be needed to assess this risk.

Summary

Adipotide (FTTP/Prohibitin-TP01) represents a mechanistically unique approach to adipose tissue research. By selectively targeting the blood vessels supplying white fat through prohibitin-directed vascular homing, coupled with a mitochondria-disrupting proapoptotic payload, Adipotide causes fat tissue to undergo ischemic death — a mechanism fundamentally different from metabolic, hormonal, or lipolytic strategies studied elsewhere in obesity research.

The 2011 primate study remains the landmark finding: 11% weight loss and 39% abdominal fat reduction in obese rhesus monkeys over 28 days. These results demonstrated proof-of-concept for vascular targeting as an approach to fat reduction and validated the underlying biology of prohibitin as an adipose vascular marker.

However, the same study identified renal toxicity as a significant safety concern, reflecting the incomplete tissue selectivity of the prohibitin-targeting approach. The kidney’s dense vasculature makes it vulnerable to off-target vascular disruption, and the observed dose-dependent renal effects represent the primary obstacle to further translational development.

Key points for researchers:

• Unique mechanism — Adipotide does not act on adipocytes directly; it destroys their blood supply via vascular targeting, a strategy adapted from anti-cancer research
• Primate data — The most significant evidence comes from a single 28-day rhesus monkey study (Barnhart et al., 2011, Science Translational Medicine)
• No human data — No clinical trials have been conducted; all safety and efficacy information is preclinical
• Renal safety concern — Dose-dependent kidney toxicity was observed in the primate model, the most significant identified risk
• Research tool value — Beyond fat reduction applications, Adipotide has contributed to understanding of vascular zip codes, prohibitin biology, and tissue-selective drug delivery
• Not a GLP-1 approach — Completely distinct mechanism from incretin-based strategies; useful for comparative research on different approaches to adipose biology

Adipotide remains an active area of interest in vascular biology and targeted peptide research, though significant safety challenges must be addressed before any translational application could be considered.

---

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Barnhart et al.	2011	Original Research	Adipotide peptidomimetic causes weight loss and improved insulin resistance in obese monkeys	PMC3666164
Kim et al.	2010	Original Research	Proapoptotic peptide targeting adipose endothelium reduces food intake and body weight	PMC2844838
Kim et al.	2012	Original Research	Rapid weight-independent glucose tolerance improvement via adipose tissue targeting	PMC3425411
Fang et al.	2020	Review	Systems biology approaches to vascular-targeted therapy for obesity	PMC7373796
Luo et al.	2025	Review	Adipose tissue-targeted drug delivery for obesity treatment	PMC12377096
Misra et al.	2013	Review	Obesity pharmacotherapy including vascular-targeted approaches	PMC3584306
Kolonin et al.	2004	Original Research	Reversal of obesity by targeted ablation of adipose tissue vasculature	PubMed 15205477

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research on Adipotide (FTTP). It does not constitute medical advice, treatment recommendations, or an endorsement of Adipotide for any therapeutic purpose. Adipotide has not been approved by the FDA or any regulatory agency for human use. The research discussed herein is preclinical (animal studies), and results from such studies may not translate to human outcomes. Significant safety concerns, particularly regarding renal toxicity, have been identified in primate models. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving this compound.

NorthPeptide supplies research-grade peptides for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes. https://northpeptide.com/products/adipotide-fttp